Overview
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-12-31
2022-12-31
Target enrollment:
Participant gender: